FY2025 · ended Dec 31, 2025 · Revenue $53.74M · Filed Mar 10, 2026
Q32 Bio Inc. (QTTB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $53.7 million and net income of $29.8 million. Free cash flow was -$33.5 million. As of Sep 30, 2026 it held $289.6 million in cash and investments and $5.1 million in total debt.
Revenue
$53.74M
Net income
$29.82M
+162.5% vs prior year
Operating cash flow (TTM)
$-20.02M
+48.4% vs year-ago TTM
Free cash flow (TTM)
$-20.07M
+48.3% vs year-ago TTM
EPS
$2.42
+136.8% vs prior year
Dividend per share
None
Shares outstanding
14.63M
+19.9% vs prior year
Net cash
$284.46M
as of Sep 30, 2026
Operating margin
31.5%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- QTTB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1661998
- Former names
- Q32 Bio Inc. (until Nov 4, 2026); Homology Medicines, Inc. (until Mar 22, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $53.7M | $0 | $1.2M | $3.2M | $34.0M |
| Operating income | $16.9M | -$66.1M | -$48.3M | -$133.3M | -$95.9M |
| Net income | $29.8M | -$47.7M | -$53.7M | -$5.0M | -$95.8M |
| Diluted EPS | $2.42 | -$6.58 | -$153.96 | -$0.09 | — |
| Operating cash flow | -$33.5M | -$67.7M | -$18.7M | -$113.7M | -$109.8M |
| Free cash flow | -$33.5M | -$67.8M | -$18.7M | -$114.9M | -$112.1M |
| Total assets | $61.8M | $92.3M | $47.1M | $228.5M | $211.7M |
| Total liabilities | $19.8M | $86.7M | $118.5M | $50.5M | $42.1M |
| Stockholders' equity | $42.0M | $5.7M | -$182.9M | -$130.7M | $169.7M |
| Cash and investments | $48.3M | $78.0M | $69.0M | $175.0M | $155.9M |
| Total debt | $5.6M | $6.2M | $6.8M | $29.5M | $23.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
All 588 Q32 Bio Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.